Cybin initiates paradigm: a multinational pivotal phase 3 program evaluating cyb003 for the adjunctive treatment of major depressive disorder and reports second quarter financial results

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the initiation of paradigmtm, its phase 3 pivotal program evaluating the efficacy and safety of cyb003 for the adjunctive treatment of major depressive disorder (“mdd”). the program name, paradigm, represents the.
CYBN Ratings Summary
CYBN Quant Ranking